Key Takeaways
- Fianlimab, Regeneron’s investigational melanoma treatment, did not achieve its primary endpoint in a late-stage clinical trial when compared to Merck’s blockbuster Keytruda.
- The fianlimab-Libtayo combination therapy failed to demonstrate statistically significant progression-free survival benefits.
- Shares of REGN tumbled 11% to $618 during premarket hours following the announcement.
- Wall Street analysts responded with downgrades and reduced price targets; Citi shifted to Neutral from Buy, cutting its forecast to $700 from $900.
- RBC Capital reduced its projection to $707, highlighting this failure as another in a series of recent development challenges.
Shares of Regeneron Pharmaceuticals experienced a significant decline in early Monday trading after the biotech company disclosed that its investigational cancer therapy fianlimab had fallen short in a pivotal late-stage clinical study.
Regeneron Pharmaceuticals, Inc., REGN
The stock plummeted 11% to $618 before the market opened. The news came via a Friday evening announcement detailing the Phase 3 study outcomes.
The clinical trial evaluated fianlimab, an immunotherapy candidate for treating advanced melanoma, when used alongside Regeneron’s existing therapy Libtayo. This combination faced off against Merck’s powerhouse cancer drug Keytruda, which ranks among the top-selling oncology medications globally.
Researchers enrolled 1,546 participants divided into four treatment arms — a high-dose combination regimen, a low-dose combination regimen, Keytruda paired with placebo, and Libtayo paired with placebo.
The investigational therapy failed to demonstrate a statistically meaningful enhancement in progression-free survival. Put simply, the drug didn’t successfully slow disease advancement or reduce mortality when stacked against Keytruda.
While a higher-dose formulation of the fianlimab-Libtayo pairing did demonstrate numerical superiority versus Keytruda, this advantage fell short of achieving statistical significance — the threshold required to establish clinical relevance.
The disappointing outcome triggered an immediate response from Wall Street, with numerous analysts revising their outlooks and reducing price projections.
Analyst Community Responds
Geoff Meacham from Citi Research downgraded Regeneron to Neutral from Buy and dramatically reduced his price objective to $700 from $900. He emphasized that eliminating fianlimab from financial projections leaves the company without “incremental positive catalysts” to support a premium stock valuation.
Jefferies analyst Akash Tewari characterized the trial miss as “not particularly” unexpected, describing it as confirmation of the bearish thesis. Despite this, he maintained a Buy recommendation while modestly lowering his target to $870 from $890 and removing fianlimab from his financial models.
RBC Capital decreased its price objective to $707 from $762 while maintaining a Sector Perform stance. The firm had previously projected peak risk-adjusted revenue of $1.6–$1.8 billion for fianlimab in this specific indication — projections now entirely eliminated.
Development Challenges Accumulate
RBC characterized the fianlimab disappointment as symptomatic of an emerging trend. The firm referenced additional recent challenges including an unsuccessful itepekimab study, a less favorable regulatory designation for Eylea HD, and production complications.
Eylea from Regeneron posted a 10% revenue decline in the first quarter, which had already pressured shares earlier this year. Truist Securities lowered its price forecast to $769 citing regulatory holdups, though maintained a Buy rating based on better-than-anticipated Q1 financial performance.
Not every analyst has adopted a pessimistic stance. BofA Securities reaffirmed a Buy recommendation with an $860 price objective despite the clinical setback. Jefferies similarly maintained its Buy position.
On a more optimistic note, Dupixent — developed jointly with Sanofi — continues its expansion trajectory, entering additional treatment areas and surpassing revenue forecasts. Eylea HD is reportedly regaining momentum, and Regeneron’s balance sheet reflects greater cash holdings than outstanding debt.
According to InvestingPro intelligence, thirteen Wall Street analysts have lowered their earnings forecasts for the company’s next reporting period.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
